Innate Pharma S.A. (EPA:IPH)
France · Delayed Price · Currency is EUR 1.316
-0.034 (-2.52%)
Oct 2, 2026, 5:35 PM CET
Innate Pharma Revenue
Innate Pharma had revenue of 5.66M EUR in the half year ending June 30, 2026, a decrease of -54.13%. This brings the company's revenue in the last twelve months to 9.81M, down -22.38% year-over-year. In the year 2025, Innate Pharma had annual revenue of 9.01M, down -55.25%.
Revenue (ttm)
9.81M
Revenue Growth
-22.38%
P/S Ratio
12.90
Revenue / Employee
81.73K
Employees
120
Market Cap
126.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.01M | -11.12M | -55.25% |
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | 85.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 60.21M |
| Cellectis | 55.86M |
| Fermentalg | 13.38M |
| Transgene | 7.21M |
| Sensorion | 6.16M |
| ABIONYX Pharma | 4.06M |
| Adocia | 2.98M |
Innate Pharma News
- 15 hours ago - Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22 - Nasdaq
- 15 days ago - Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript - The Motley Fool
- 15 days ago - Innate Pharma Q2 Earnings Call Highlights - MarketBeat
- 15 days ago - Innate Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 15 days ago - Innate Pharma Earnings release: Q2 2026 - Filings
- 15 days ago - Innate Pharma Earnings release: Q2 2026 - Filings
- 15 days ago - Innate Pharma Quarterly report: Q2 2026 - Filings
- 15 days ago - Innate Pharma Slides: Q2 2026 - Filings